Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery

Fineline Cube Jan 12, 2026
Company Deals

Haisco Licenses COPD Drug HSK39004 to AirNexis for $1.06 Billion

Fineline Cube Jan 12, 2026
Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia

Fineline Cube Jan 12, 2026
Company Drug

Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101

Fineline Cube Dec 23, 2024

Changchun BCHT Biotechnology Co., Ltd (SHA: 688276), a China-based biotechnology company, has announced receiving clinical...

Company Drug

Shenzhen Chipscreen Biosciences Gets NMPA Approval for CS231295 Solid Tumor Study

Fineline Cube Dec 23, 2024

Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321), a China-based biopharmaceutical company, has announced receiving the...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval to Test SHR-1681 in Clinical Trials

Fineline Cube Dec 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that it has received approval from...

Company Drug

CSPC Pharmaceutical’s SYH9017 Receives NMPA Clearance for Weight Management Clinical Trial

Fineline Cube Dec 23, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced clinical clearance from the National...

Company Drug

CSPC Pharmaceutical Group Receives NMPA Approval for Two Antibody-Drug Conjugates

Fineline Cube Dec 23, 2024

China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received separate...

Company Drug

CanSino Biologics Initiates Phase I/II Study for CS-2036 Polio Vaccine with Gates Foundation Support

Fineline Cube Dec 23, 2024

CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study...

Company Drug

Innovent Biologics’ Taletrectinib Wins NMPA Approval for ROS1+ NSCLC Treatment

Fineline Cube Dec 23, 2024

China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving marketing approval from the National Medical...

Company Medical Device

MicroPort Scientific Corp. Receives NMPA Approval for FireRaptor Coronary Atherectomy System

Fineline Cube Dec 23, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...

Company

Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO

Fineline Cube Dec 22, 2024

On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera...

Company Drug

YolTech Therapeutics’ YOLT-201 Advances in ATTR Treatment Clinical Trial

Fineline Cube Dec 21, 2024

Shanghai, China, December 21, 2024 — YolTech Therapeutics today announced that its proprietary in vivo...

Company Deals

Wuhan Weike Medical Technology Secures Series C Funding to Boost Cardiovascular Innovation

Fineline Cube Dec 21, 2024

Wuhan Weike Medical Technology Co., Ltd., known as “Weike Medical,” has officially announced the successful...

Company Deals

Sumitomo Pharma Expands Collaboration with Shanghai Pharmaceuticals for Prescription Drug Co-Marketing

Fineline Cube Dec 20, 2024

Japan-based Sumitomo Pharma Co., Ltd (TYO: 4506) has announced an expanded Contract Sales Organization (CSO)...

Company Medical Device

Boston Scientific’s Next-Gen IVUS System AVVIGO+ Approved by China’s NMPA for Coronary Disease Use

Fineline Cube Dec 20, 2024

US-based Boston Scientific Corporation (NYSE: BSX) has announced that China’s National Medical Products Administration (NMPA)...

Company Deals

Guardant Health and Boehringer Ingelheim Join Forces to Develop Guardant360 CDx for Zongertinib Companion Diagnostic

Fineline Cube Dec 20, 2024

US-based precision oncology specialist Guardant Health, Inc. (NASDAQ: GH) has entered into an agreement with...

Company Drug

Roche’s Prasinezumab Shows Promise in Phase IIb PADOVA Study for Early-Stage Parkinson’s Disease

Fineline Cube Dec 20, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has published results from the Phase IIb PADOVA study...

Company Deals

Hainan Boao Lecheng and Sanofi Partner with Paris-Saclay Cancer Cluster for Advanced Cancer Treatments

Fineline Cube Dec 20, 2024

The Hainan Boao Lecheng International Medical Tourism Pilot Zone, in collaboration with France’s major Sanofi’s...

Company Drug

Sichuan Kelun-Biotech Launches Sacituzumab Tirumotecan for Triple Negative Breast Cancer in China

Fineline Cube Dec 20, 2024

China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced the commercial launch of its...

Company Deals

WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio

Fineline Cube Dec 20, 2024

China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic...

Company Deals

MGI Tech Co., Ltd Partners with Sabin Group to Enhance Genetic Sequencing in Brazil

Fineline Cube Dec 20, 2024

China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) has entered into a strategic...

Company Deals

Astellas Pharma Inks Licensing Deal with Sangamo Therapeutics for Neurological AV Capsid STAC-BBB

Fineline Cube Dec 20, 2024

Japan-based Astellas Pharma Inc. (TYO: 4503) has revealed a strategic licensing agreement with US-based Sangamo...

Posts pagination

1 … 182 183 184 … 607

Recent updates

  • FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development
  • Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia
  • Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA
  • Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity
  • Pierre Fabre Partners with Iktos on AI-Driven Oncology Drug Discovery
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Company Drug

Huadong Medicine’s DR10624 Wins Breakthrough Designation for Severe Hypertriglyceridemia

Medical Device

Dongcheng Pharma’s PSMA PET Agent [18F] Spiritide NDA Accepted by NMPA

Company

Novartis to Build $23 Billion RLT Facility in Florida, Expanding Cancer Therapy Capacity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.